Thursday, August 06, 2009

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type KRAS Population

Phase 3 Results Reinforce Importance of KRAS Testing

THOUSAND OAKS, Calif. – Aug. 6 – Amgen (Nasdaq: AMGN) today announced that Vectibix (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC).

Read the rest of this entry

Posted in Press Releases

Monday, August 03, 2009

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events

THOUSAND OAKS, Calif. – Aug. 3 – Amgen (Nasdaq: AMGN) today announced positive top-line results from a pivotal Phase 3 head-to-head trial evaluating denosumab administered subcutaneously versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma.

Read the rest of this entry

Posted in Press Releases

Monday, July 27, 2009

Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

Amgen to Retain Full Rights for Denosumab in the United States and Canada and for Oncology Indications in Europe GlaxoSmithKline Will Commercialize Denosumab for PMO and Oncology in Emerging Markets

THOUSAND OAKS, Calif. and LONDON – July 27 – Amgen (Nasdaq: AMGN) andGlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) inEurope, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States (U.S.) and Canada and for all oncology indications in Europe and specified markets.

Read the rest of this entry

Posted in Press Releases

Monday, July 27, 2009

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 Billion Second Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.25 2009 Total Revenue Trending Towards Upper End of Current Guidance Range of $14.4-$14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range of $4.55-$4.75 Raised to $4.80-$4.95

THOUSAND OAKS, Calif. –July 27 – Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.29 for the second quarter of 2009, an increase of 13 percent compared to$1.14 for the second quarter of 2008. Adjusted net income increased 6 percent to $1,311 million in the second quarter of 2009 compared to $1,235 million in the second quarter of 2008.

Read the rest of this entry

Posted in Press Releases

Monday, July 20, 2009

Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium

THOUSAND OAKS, Calif. – July 20, 2009 – From July 18-20, more than 260 of the country’s brightest undergraduate students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to bring together program participants and help them apply their science research experiences into future science careers.

Read the rest of this entry

Posted in Philanthropy, Press Releases